Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Multiple System Atrophy (MSA) is a rare neurodegenerative disease, clinically defined by a combination of autonomic dysfunction and motor involvement, that may be predominantly extrapyramidal (MSA-P) or cerebellar (MSA-C). Although dementia is generally considered a red flag against the clinical diagnosis of MSA, in the last decade the evidence of cognitive impairment in MSA patients has been growing. Cognitive dysfunction appears to involve mainly, but not exclusively, executive functions, and may have different characteristics and progression in the two subtypes of the disease (i.e., MSA-P and MSA-C). Despite continued efforts, combining imaging studies as well as pathological studies, the physiopathological bases of cognitive involvement in MSA are still unclear. In this view, the possible link between cardiovascular autonomic impairment and decreased cognitive performance, extensively investigated in PD, needs to be clarified as well. In the present study, we evaluated a cohort of 20 MSA patients (9 MSA-P, 11 MSA-C) by means of a neuropsychological battery, hemodynamic assessment (heart rate and arterial blood pressure) during rest and active standing and bedside autonomic function tests assessed by heart rate variability (HRV) parameters and sympathetic skin response (SSR) in the same experimental session. Overall, global cognitive functioning, as indicated by the MoCA score, was preserved in most patients. However, short- and long-term memory and attentional and frontal-executive functions were moderately impaired. When comparing MSA-P and MSA-C, the latter obtained lower scores in tests of executive functions and verbal memory. Conversely, no statistically significant difference in cardiovascular autonomic parameters was identified between MSA-P and MSA-C patients. In conclusion, moderate cognitive deficits, involving executive functions and memory, are present in MSA, particularly in MSA-C patients. In addition, our findings do not support the role of dysautonomia as a major driver of cognitive differences between MSA-P and MSA-C.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243310PMC
http://dx.doi.org/10.3389/fneur.2022.912820DOI Listing

Publication Analysis

Top Keywords

msa-p msa-c
20
executive functions
12
cognitive
8
autonomic dysfunction
8
multiple system
8
system atrophy
8
msa patients
8
cardiovascular autonomic
8
heart rate
8
msa-c patients
8

Similar Publications

Molecular imaging based spatiotemporal dynamics progression of brain glucose metabolism in multiple system atrophy.

Eur J Nucl Med Mol Imaging

August 2025

Department of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Objective: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with complex clinical manifestations, which is essential for patient management and mechanistic understanding of MSA. In this study, we aimed to use disease progression modeling (SuStaIn model) to elucidate the in vivo spatiotemporal progression patterns of brain glucose metabolism in MSA patients, and investigate the differential profiles of clinical characteristics and dopaminergic function among the identified progression-related subtypes.

Methods: A total of 192 participants (117 MSA patients [70 MSA-P, 47 MSA-C] and 75 healthy controls) who underwent [F]FDG PET scans, with 82 MSA patients additionally receiving [F]FP-CIT PET imaging were retrospectively enrolled.

View Article and Find Full Text PDF

Disease Progression in Multiple System Atrophy: The ASPIRE Multi-Modal Biomarker Study.

Ann Neurol

August 2025

Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse; INSERM, University of Toulouse, CHU of Toulouse, Toulouse, France.

Objective: The objective of this study was to characterize changes in candidate biomarkers in early multiple system atrophy (MSA) and identify baseline predictors of faster progression.

Methods: This 1-year, multicenter, prospective study assessed clinical, neuroimaging (3T-magnetic resonance imaging [MRI], dopamine transporter single-photon emission computed tomography [DaT-SPECT]), and neurofilament light chain (NfL) changes in patients with early MSA (< 5 years from symptom onset) and healthy controls (HCs). Clinical and biomarker changes from baseline to 6 months (M6) and 12 months (M12) were analyzed.

View Article and Find Full Text PDF

Background: Multiple system atrophy (MSA) is a fatal alpha-synucleinopathy characterized by variable combinations of parkinsonism and autonomic and cerebellar dysfunctions.

Objective: We aimed to prospectively study the natural history of probable MSA, including cardiovascular autonomic dysfunction (CAD) and serum alpha-synuclein.

Methods: Sixty probable MSA patients (MSA-P = 19; MSA-C = 41) and 30 age-and-gender-matched healthy controls were recruited.

View Article and Find Full Text PDF

Background: The differentiation between multiple system atrophy (MSA) and Parkinson's disease (PD) based on clinical diagnostic criteria can be challenging, especially at an early stage. Leveraging deep learning methods and magnetic resonance imaging (MRI) data has shown great potential in aiding automatic diagnosis.

Objective: The aim was to determine the feasibility of a three-dimensional convolutional neural network (3D CNN)-based approach using multimodal, multicentric MRI data for differentiating MSA and its variants from PD.

View Article and Find Full Text PDF

Background: Dorsal nigral hyperintensity (DNH) abnormality associated with excessive iron deposition in the substantia nigra, is recognized as an imaging characteristic of Parkinson's disease (PD) and can be effectively visualized using 7T MRI. This study was aimed to develop and validate the optimal DNH assessment method as a biomarker for PD, idiopathic rapid eye movement sleep behavior disorder (iRBD), and Parkinson-plus syndromes, and to explore the nigral iron deposition patterns in these diseases.

Methods: Three-dimensional gradient-echo T2*-weighted images were acquired by 7T MRI from a total of 402 patients and 100 healthy controls (HCs) in two independent cohorts (development and validation cohorts).

View Article and Find Full Text PDF